SYMBIOTEC PHARMALAB LTD (SYMBIOTEC): SYMBIOTEC 52 Week High Streak: Consecutive High Analysis

SYMBIOTEC 52 Week High Streak has now held for its second straight session, with the stock trading within 2% of its 52-week high across the streak and moving up 3.72% over that span. The latest price action keeps the stock near its one-year peak, while the latest Univest figures confirm the pattern but do not establish a company-specific catalyst for the continued move. For readers tracking SYMBIOTEC 52 Week High Streak, the main point is the repetition, not just the day’s move.

At 01 October 2026 at 9:52 AM IST, SYMBIOTEC Share Price Today stood at Rs 1186.95, above the previous close of Rs 1176.05 after opening at Rs 1197.8 and moving between Rs 1159.85 and Rs 1222. The company’s market capitalisation stands at Rs 7353.15 crore, which places the SYMBIOTEC Share Price near its yearly high without turning this into a new all-time high claim. For investors, the repeated-high pattern is more informative than a one-session move because it shows the stock is staying close to its peak.

SYMBIOTEC 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 1,186.95
Previous Close	Rs 1,176.05
Today's Move	+Rs 10.9 (+0.93%)
Open	Rs 1,197.8
High	Rs 1,222
Low	Rs 1,159.85
Market Capitalisation	Rs 7,353.15 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,186.95 versus the previous close of Rs 1,176.05, a rise of 0.93%. The stock opened at Rs 1,197.8, reached a high of Rs 1,222 and touched a low of Rs 1,159.85.

SYMBIOTEC Share Price Today was Rs 1186.95, up Rs 10.9 or 0.93% from the previous close. The stock opened at Rs 1197.8, touched a high of Rs 1222 and a low of Rs 1159.85, and was trading within that range as of 01 October 2026 at 9:52 AM IST. The move keeps SYMBIOTEC Share Price close to the 52-week high zone and continues the visible pattern behind the SYMBIOTEC 52 Week High Streak. The company’s market capitalisation at Rs 7353.15 crore also gives context to the move, showing that the stock is trading at a meaningful equity value level while remaining in a repeated-near-high phase. For readers following SYMBIOTEC Stock News, the point here is the persistence of the price behaviour rather than a single sharp jump. That is why the current SYMBIOTEC Stock Performance deserves attention in the broader SYMBIOTEC Stock Analysis.

What the Repeated 52-Week Highs Show

SYMBIOTEC 52 Week High Streak now reflects a second straight session of trading near the one-year peak, and that repeated pattern is the key signal from the market data. The current streak has delivered a cumulative move of 3.72%, which helps frame the move across multiple sessions rather than a single day. The latest setup also shows that the stock is still trading near a one-year high rather than at a new record high, so this remains a 52-week high event and not an all-time high event. That distinction matters for readers searching for SYMBIOTEC New One Year High or SYMBIOTEC Back To Back 52 Week Highs. The pattern confirms durability near the top of the range, but the figures alone do not establish a fresh company-specific trigger beyond the news item noted above. In that sense, the SYMBIOTEC 52 Week High Streak is more about repetition than a one-off spike.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 7,353.15 crore
P/E Ratio	68.76x
P/B Ratio	5.04x
ROE	11.22%
ROCE	12.41%
EPS	Rs 17.1
Book Value Per Share	Rs 233.38
Dividend Yield	0%

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 68.76x, P/B 5.04x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.

SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7353.15 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 68.76x, P/B at 5.04x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.95x, median ROE of 11.74%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	68.76x
Benchmark Median P/E	27.95x
Benchmark Average P/E	41.62x
Benchmark P/E Range	0x to 688.17x
Company P/B Ratio	5.04x
Benchmark Median P/B	2.84x
Company ROE	11.22%
Benchmark Median ROE	11.74%
Company ROCE	12.41%
Benchmark Median ROCE	13.63%
Company Market Capitalisation	Rs 7,353.15 crore
Benchmark Median Market Cap	Rs 765.11 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.76x, which is above the benchmark median of 27.95x, a difference of +146.01%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.74%, a difference of -4.43%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.63%, a difference of -8.95%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Why SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) May Be Moving Today

According to recent news reports, SYMBIOTEC Stock News includes a partnership involving its subsidiary Knovea and a major global pharmaceutical company for US sales of two dual chamber vial products. That development may be linked to the renewed attention around SYMBIOTEC Share Price Today, as it points to a possible expansion in market reach and revenue streams. The news does not prove causation, but it coincides with the stock’s SYMBIOTEC 52 Week High Streak and may help explain why the name remains among Stocks At One Year High Today and other Stocks In News Today.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Innova Captab Ltd.	INNOVACAP	7,282.44	42.4	5.84	13.75	15.04
Bliss GVS Pharma Ltd.	BLISSGVS	7,550	54.29	6	12.11	17.4
Sanofi India Ltd.	SANOFI	7,072.59	21.76	8.53	44.5	55.46
Supriya Lifescience Ltd.	SUPRIYA	7,652.71	38.58	6.26	19.06	25.3
Morepen Laboratories Ltd.	MOREPENLAB	6,509.69	49.13	5.3	7.96	10.19

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.76x compared with the displayed peer median of 42.4x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 17.4%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,353.15 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)

• SYMBIOTEC 52 Week High Streak has extended for a second straight session, keeping the stock near its one-year peak.
• The cumulative move across the streak stands at 3.72%, which is the key multi-session read for SYMBIOTEC Share Price.
• SYMBIOTEC Fundamental Analysis shows a P/E of 68.76 and a P/B of 5.04, both above the industry median.
• The latest news item on Knovea’s US sales partnership is the only specific development that may be linked to SYMBIOTEC Stock News flow today.
• SYMBIOTEC Market Cap at Rs 7353.15 crore places the company well above the industry median market value.

About SYMBIOTEC PHARMALAB LTD (SYMBIOTEC)

SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector within the Pharmaceuticals & Drugs industry. The company’s SYMBIOTEC Share Price is now being tracked closely because it has stayed near its 52-week high for a second straight session. Its latest market capitalisation is Rs 7353.15 crore, and the company is valued at a premium to the industry median on earnings and book metrics. For readers scanning SYMBIOTEC Company News and SYMBIOTEC Stock Performance, the current focus is on how long the stock can remain near its yearly peak.

That makes SYMBIOTEC NSE and SYMBIOTEC BSE watchlists relevant for investors who follow pharma names with a sustained high-price pattern. The company also sits within a peer group that includes Innova Captab, Bliss GVS Pharma, Sanofi India, Supriya Lifescience and Morepen Laboratories. The latest SYMBIOTEC Stock Analysis therefore sits at the intersection of price behaviour, valuation and sector positioning.

Frequently Asked Questions

What does the SYMBIOTEC 52 Week High Streak mean?

Ans. It means SYMBIOTEC has traded within 2% of its 52-week high for a second straight session. The pattern is useful because it shows the stock is staying near its yearly peak rather than only touching that zone once.

How many sessions has SYMBIOTEC traded near its 52-week high?

Ans. According to latest Univest figures, the streak now covers two consecutive sessions. The stock has remained close to its 52-week high across both sessions, which is why the repeated-high pattern is being tracked.

What is the cumulative move in the SYMBIOTEC 52 Week High Streak?

Ans. The cumulative move across the streak is 3.72%. That figure captures the multi-session price change and is more relevant here than the day-to-day move alone for understanding the repeated-high setup.

Is SYMBIOTEC at a new all-time high?

Ans. No. The latest numbers confirm a 52-week high pattern, not an all-time high claim. The article should be read as a one-year high streak update, not as a lifetime record update.

What are the latest SYMBIOTEC Share Price Today levels?

Ans. SYMBIOTEC was trading at Rs 1186.95 after opening at Rs 1197.8 and moving between Rs 1159.85 and Rs 1222. The price remained near its yearly high zone during the period covered here.

How does SYMBIOTEC compare with peers on valuation?

Ans. The stock trades at a P/E of 68.76 and a P/B of 5.04, which is above the industry median. Compared with peers such as Innova Captab, Bliss GVS Pharma and Supriya Lifescience, the valuation is on the richer side.

What fundamental metrics matter most for SYMBIOTEC Stock Analysis?

Ans. Investors usually look at P/E, P/B, ROE, ROCE, EPS, book value and market capitalisation. For SYMBIOTEC, the current mix shows a premium valuation alongside ROE of 11.22% and ROCE of 12.41%.

What should investors monitor next in SYMBIOTEC Stock News?

Ans. Investors may monitor whether the stock keeps trading near its 52-week high, whether any new company news appears, and whether the valuation remains supported by financial performance. The repeated-high pattern is the key item to watch.

Track SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Share Price on Univest

Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.